Italia markets close in 4 hours 42 minutes

FTSE MIB
34.325,06
-334,49(-0,97%)
Dow Jones
38.852,86
-216,74(-0,55%)
Nasdaq
17.019,88
+99,08(+0,59%)
Nikkei 225
38.556,87
-298,50(-0,77%)
Petrolio
80,43
+0,60(+0,75%)
Bitcoin EUR
62.559,90
-559,25(-0,89%)

NVCR Jan 2026 17.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

10,70

0,00

(0,00%)

In data: 09:34AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in